Saving Vaccines in the Americas: A Framework for Vaccine Safety Training
|
|
- Christopher Wheeler
- 5 years ago
- Views:
Transcription
1 Saving Vaccines in the Americas: A Framework for Vaccine Safety Training Elizabeth K. Lutz, MPH Candidate Colorado School of Public Health Edwin J. Asturias, MD Director for Latin America, Center for Global Health Associate Professor, Departments of Pediatrics & Epidemiology A collaboration between the Center for Global Health & the Pan American Health Organization Global Health Symposium, November 15, 2013 UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY UNIVERSITY OF NORTHERN COLORADO
2 Importance of Vaccine Safety Use of high quality, safe, & effective vaccines prevents between 2 and 3 million deaths each year Expanded Access EPI, GAVI Alliance, Decade of Vaccines Global Vaccine Action Plan Vaccines are not 100% safe and effective Rare, adverse events following immunization (AEFI) Preventable Programmatic Errors Risk management systems are essential to maintain public confidence, especially as rumors and fears threaten immunization programs
3 The Current Situation Vaccine Safety Blueprint 2011 Guidelines to ensure minimal vaccine safety capacity in all countries Pan American Vaccine Safety Summit 2012 Hosted by Center for Global Health with 10 countries represented Enhance healthcare worker training capacity at local, subnational and national levels PAHO approached Center of Global Health to partner on training program development
4 Goal and Methods Objective: To develop a basic, intermediate, and advanced level vaccine safety training course to be delivered online to local, subnational, and national healthcare workers in the Region of the Americas Landscape Analysis What already exists? Key Informant Roundtable What experts think are the gaps? Focus Group What are perceived needs? Vaccine Safety Training Course Design
5 Landscape Analysis Systematic review of the literature and existing training courses in: Pharmacovigilance/Pharmacoepidemiology (Drugs and Vaccines) Vaccine safety and risk/benefit assessment Vaccinology and related topics 30 programs were identified and evaluated Content, Audience, Delivery, Accessibility
6 Landscape Findings/Gaps Content Limited courses targeting LMICs and Region Developed world specific not addressing infrastructure and resource challenges Pharmacovigilance of all medicines, not Vaccine Specific Delivery 2 3 day workshops Fragmented topics Limited Availability & Accessibility Facilitators; financial and staff capacity to travel Online courses: limited in modern features related to interactive learning
7 Key Informant Roundtable 3 PAHO experts from Immunization Division including the Regional Advisor of the Comprehensive Family Immunization Program Confirmed need for new way to approach VS training Clarified gaps/needs discussed in landscape analysis Authorities from Ministry of Health, Haiti, PAHO, CDC & GAVI visit a Haitian vaccination center during Vaccination Week 2013, photo credit: PAHO
8 Focus Group Objectives What are the gaps and priorities to meet training needs in vaccine safety in the Region of the Americas? Value of vaccine safety Current state of vaccine safety knowledge Gaps and priorities for training Audience (target levels and depth) Partners to work with in the Region To inform development of an online vaccine safety course for local, subnational and national levels
9 Focus Group Participants HAITI National Immunization Program, PAHO COLOMBIA Immunization Group Dep t of Public Health Risk Surveillance & Analysis National Institute of Health, Preventable Diseases NICARAGUA National Immunization Program, PAHO BRAZIL National Regulatory Program Manager ANVISA (Nat l Health Surveillance Agency) CHILE Immunization Department Health Planning Division, Ministry of Health ARGENTINA Vaccine Safety Coordinator National Immunization Program, Ministry of Health
10 Results: Value of Vaccine Safety Do you believe there is value in developing vaccine safety work in the region today? Why do you think this is valuable? Argentina Brazil Chile Colombia Haiti Nicaragua Value? Yes Yes Yes Yes Yes Yes Why Maintain confidence in National Immunization Program Introduction of new vaccines Notification of adverse events following immunization By law, job competencies To confront crisis situations Rotation of personnel It is extremely important in order to maintain confidence in healthcare professionals and to maintain vaccination coverage rates Argentina
11 ARGENTINA BRAZIL CHILE COLOMBIA HAITI NICARAGUA TOTALS GAPS Communication X X X X X X 6 Investigation X X X 3 Causality Assessment X X X 3 Notification X X X 3 Diagnosis of AEFI X X 2 Crisis Response/Mgmt X X 2 CONTENT PRIORITIES Communication X X X 3 Investigation X X X X 4 Causality Assessment X X X 3 Notification X X 2 Diagnosis of AEFI X X 2 Concept of AEFI X X 2 Vaccine Administration X X 2 Cold Chain X X 2 Analysis X X 2 Anti Vaccination Groups X X 2 Technical/Clinical Aspects X X 2 Response X X 2
12 An Innovative Proposal New Paradigm: Natural history of an Adverse Event Following Immunization (AEFI) Online availability Modern features for flexible training delivery 3 level progressive module training Certification potential
13 Syllabus Proposed to PAHO
14 Conclusion Enhanced vaccine safety training efforts in the Americas is valued and needed across countries and by PAHO Validates findings from the Landscape Analysis that there are gaps in existing training Content development based on identified gaps/priorities Important step in building workforce capacity to protect National Immunization Programs and public safety
15 Acknowledgments Edwin J. Asturias, MD Director for Latin America, Center for Global Health Associate Professor, Departments of Pediatrics & Epidemiology PAHO Family & Community Health Immunization Program Carlos Castillo Solórzano, MD (Regional Advisor) Pamela Bravo, MPH (Immunization Division Officer) Focus Group Participants
16 Thank you! Elizabeth K. Lutz, MPH Candidate
17 Potential Platforms Identified in Landscape Analysis (Identified 12)
18 New Paradigm: Natural History of an AEFI EJ Asturias AEFI Local Health Center or Hospital Health District Immunization Program System National Media Y Politics What, Where When, How? Cause, Why? Possible? Regulatory Authority Regional & Global DETECTION Risk? Change? Data? SURVEILLANCE & REPORTING SYSTEM INVESTIGATION & DATA MANAGEMENT MANAGEMENT COMMUNICATION PLAN, RISK & RECOMMENDATIONS
19 AEFI Classification Adverse event following immunization (AEFI): any untoward medical occurrence which follows immunization and which does not necessarilty have a causal relationship with the usage of the vaccine. The adverse event may be any unfavorable or unintended sign, abnormal laboratory finding, symptom or disease. AEFI Classification Definition Example Vaccine product related reaction An AEFI that is caused or precipitated by a vaccine due to one or more of the inherent properties of the vaccine product Limb swelling, Redness around injection site Vaccine quality defect related reaction An AEFI that is caused or precipitated by a vaccine that is due to one or more quality defects of the vaccine product including its administration device as provided by the manufacturer Paralytic polio (manufacture failure to inactivate polio) Cold chain interruption Immunization error related reaction An AEFI that is caused by inappropriate vaccine handling, prescribing or administration and thus by its nature is preventable Inappropriate handling/administration Vial contamination Reconstitution errors Incorrect route of admin. Immunization anxiety related reaction Coincidental event An AEFI arising from anxiety about the immunization An AEFI that is caused by something other than the vaccine product, immunization error or immunization anxiety Fainting Fever with malaria, temporal association Autism
20 Communication Communication Module V: Communication I Unit 1: Perception of Risk (parents, public and HCWs) Unit 2: Communicating with Parents & Public Module VIII: Communication II Unit 1: Establishing a Strategic Risk Communication Plan & Crisis Communication Plan How to construct a message, rumor management, operational aspects Unit 2: Forming the Communication Response Team Unit 3: Damage Control Communicating with and informing stakeholders, media, public, parents Support systems (emotional, psychological, logistical, legal) Legal Aspects Unit 4: Understanding and Responding to the Anti Vaccination Movement Module XII: Communication III Unit 1: Implementing Crisis Communication Plan Unit 2: Coordination between all stakeholders (media, NRA, response team) Unit 2: Evaluating Crisis Communication Response Unit 3: Legal Aspects Unit 4: Global Communication
21 AEFI Investigation, Case Assessment, Causality Assessment Module IV: Intro to AEFI Investigation Unit 1: Basic elements of AEFI Investigation Module VII: Investigation & Case Assessment Unit 1: Investigation of Safety Signals Investigation process: back and forth Serious AEFIs, Clusters, Signals, Unexpected AEFIs to be Who to report to, feedback, etc. investigated Unit 2: Background Incidence and its Application to Signals Unit 3: Case Assessment Analysis/Background Information: Clinical History, Vaccine in question, Vaccination Process, Lab Testing, Pathology AEFI Classification/Causes o Evaluate Seriousness/Importance of Case o CIOMS Approach: Causes related to host (contraindication), vaccine (composition), system (cold chain, administration), other causes (coincidence) o Brighton Collaboration and other Case Definitions Module X: Causality Assessment Unit 1: Evaluating Causality Unit 2: Risk/Benefit Assessment Unit 3: Testing Causality: Randomized controlled clinical trials, cohort studies, case control studies, case series analyses Consistency, strength of association, specificity, temporal relation, biological plausibility
22 BASIC INTERMEDIATE ADVANCED Introduction to Vaccine Safety Module I: Introduction to Vaccine Safety Unit 1: Evolution of Vaccine Safety Unit 2: How is Vaccine Safety Evaluated Unit 3: Vaccine Types and System What is a Vaccine How Vaccines Work Types and Examples of Vaccines Overview of Immunization System Unit 4: Natural History of an AEFI AEFI Surveillance/Monitoring Module II: Unit 1: Types of Adverse Events Unit 2: Diagnosis of an AEFI Serious and Non serious AEFI Frequency of Types of AEFI Unit 3: AEFI Notification/Reporting Standard Data Collection (Core Variables) Reporting Forms Supportive Data (laboratory, pathology, verbal autopsy) Unit 4: Surveillance Systems Management of an AEFI Module III: AEFI Management Unit 1: Diagnosis/Basic Treatment (Technical/Clinical Aspects) Basic measures Module VI Unit 1: Pre registration Vaccine Safety Unit 2: Post Registration Vaccine Safety and Surveillance/Monitoring Passive, Passive Stimulated, Active and Sentinel Surveillance for Signal Detection Electronic and Paper Systems (new e SAVI system) Incorporated into other modules Module IX: Vaccine Safety Systems Management Unit 1: Developing a National System for Dealing with AEFIs Ensuring Functioning System Capacity for HCWs to Carry out Vaccine Safety Process Technology/Equipment Human Resources, Training Economic Resource Allocation Unit 2: Introduction of New Vaccines Unit 3: Vaccines in Special Populations Unit 4: Evaluating Success of Surveillance System/Monitoring Unit 5: International Surveillance/Monitoring System and Processes Module XI: AEFI Decision Making, Response and Policy Unit 1: Coordination with NRA, NITAG, AEFI Review Committees andother stakeholders
23 Competencies for Online VS Course Detection, Identification, Management of an AEFI Basic Intermediate Advanced 1A1. Identifies an event as an AEFI when an illness presents itself after vaccination and has a suspected association with the vaccine 1B1. Identifies and responds to AEFIs that may impact the immunization program at the local or subnational level 1C1. Responds and manages AEFIs and signals of national and international importance for the NIP 1A2. Defines the different types of adverse events following immunization 1A3. Applies basic measures and specific therapies to manage AEFI upon diagnosis 1A4. Participates in reporting and standard data collection of core data 1B2. Reviews and integrates standard case definitions and classification of AEFIs 1B3. Treats and manages more serious AEFIs, and coordinates investigation 1B4. Analyzes core data from AEFI reports to manage AEFI 1C2. Coordinates the integration of AEFI data and evidence, and uses the proper channels for AEFI notification and response 1C3. Ensures immunization program capacity to treat/manage AEFI 1C4. Oversees systems for processing AEFI information and feedback AEFI Investigation Basic Intermediate Advanced 2A1. Describes basic elements of an AEFI investigation and AEFI investigation process 2B1. Conducts comprehensive AEFI investigation 2C1. Conducts, coordinates, and assesses AEFI investigations 2A2. Identifies what to report and who to report to regarding an AEFI 2A3. Understands risks and benefits of specific vaccines 2B2. Detects serious AEFIs, clusters, signals and other AEFIs to be investigated 2B3. Assesses Risk/Benefit relationship between vaccine and adverse event 2B4. Understands, assesses, and uses background incidence of an investigation AEFI 2C2. Assesses/Tests causality of AEFI 2C3. Assesses Risk/Benefit relationship between vaccine and adverse events 2C4. Ability to develop local and national background incidence data for immunization program
24 Limitations Selected Sample of countries Participant Bias (work within immunization departments) Does not fully reflect healthcare worker experiences Limited representation from Caribbean countries Cannot account for vaccine safety system differences across countries (more advanced vs. less)
25 New Introductions: Pneumococcal Conjugate Vaccine (PCV) Hepatitis B (HepB) Haemophilus influenza type B (Hib) Rotavirus (RV) HPV Meningococcal Yellow Fever Typhoid Pipeline Malaria Cholera Dengue
26
Sustaining Immunization in Developing Countries: The Future We Make
Sustaining Immunization in Developing Countries: The Future We Make Global Health Summit Denver, CO 29 April 211 Jon Kim Andrus, MD Deputy Director Umbrella of protection in the Americas Measles eradication
More informationRevised AEFI Guidelines: Executive Summary
Revised AEFI Guidelines: Executive Summary Introduction: India s Universal Immunization Programme (UIP), targets around 27 million newborns and about 30 million pregnant women each year. The goal of immunization
More informationStrengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative
http://www.paho.org/provac Strengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative Cara Bess Janusz Immunization, PAHO 1 st Regional Dengue Symposium 3-4 November
More informationTaking vaccine effectiveness into public health decision making: The ProVac Example
http://www.paho.org/provac Taking vaccine effectiveness into public health decision making: The ProVac Example Evaluating dengue effectiveness workshop June 12 th, 2014 Washington, DC Cara Bess Janusz
More informationIntroduction to the ProVac Initiative
Introduction to the ProVac Initiative E-toolkit training module Nathalie El Omeiri, PAHO/WHO, Washington D.C. Family, Health Promotion and Life Course, Immunization unit, elomeirin@paho.org Contents of
More informationSafety monitoring of vaccines. Jeremy Labadie MD vaccine safety specialist
Safety monitoring of vaccines Jeremy Labadie MD vaccine safety specialist vaccines are special immunization programmes pharmacovigilance & vaccines vaccines & AEFI causality assessment of AEFI UMC and
More informationGlobal Vaccine Safety Initiative Activities Portfolio
Global Vaccine Safety Initiative Activities Portfolio 2012-2020 World Health Organization Switzerland April Activities Description Global Vaccine Safety initiative activities portfolio Introduction The
More informationPost Licensure Communication on Vaccine Safety among Regulator, Industry and Stakeholder
Post Licensure Communication on Vaccine Safety among Regulator, Industry and Stakeholder Lucky S Slamet DCVMN International Annual General Meeting, New Delhi, India, 8-10 July 2014 1 Disclaimer The information
More informationIntroduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI
Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI 2 Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making
More informationVaccine Decision-Making
Key Points Vaccine Decision-Making * Decisions on introducing new vaccines have long-term implications for immunization costs as well as logistics systems and service delivery. The choice of vaccine presentation
More informationGAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS
GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS Ranjana Kumar International Rotavirus Symposium Istanbul, 3 4 June 2008 The GAVI Alliance Public-private partnership bringing
More informationVaccines. Global impact of a preventive technology. Edwin J. Asturias, MD
Vaccines Global impact of a preventive technology Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public
More informationHow do we know vaccines are safe?
How do we know vaccines are safe? A/Professor Michael Gold Head Allergy and Immunology Women s and Children s Health Network and Discipline of Paediatrics University of Adelaide Outline Context of vaccine
More informationQuality assurance for essential medicines and health products: moving towards an harmonized approach
Quality assurance for essential medicines and health products: moving towards an harmonized approach Prequalification of vaccines David Wood QSS/EMP/WHO 12 December 2012 A growing portion of vaccines procured
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationGavi s Vaccine Investment Strategy
Gavi s Vaccine Investment Strategy Judith Kallenberg, Head of Policy WHO Product Development for Vaccines Advisory Committee Meeting Geneva, Switzerland, 7-9 September 2015 www.gavi.org Vaccine Investment
More informationUpdate on Implementation of NUV. Carsten Mantel WHO/FCH/IVB/EPI
Update on Implementation of NUV Carsten Mantel WHO/FCH/IVB/EPI Introduction of New Vaccines The continuum of activity REGULATORY NORMS & STANDARDS VACCINE SUPPLY PROCUREMENT PRICING FINANCING SURVEILLANCE
More informationAdvancing RSV maternal immunization: A gap analysis brief An analysis to identify needs for vaccine decision-making and introduction
Advancing RSV maternal immunization: A gap analysis brief An analysis to identify needs for vaccine decision-making and introduction Despite significant advances in child survival, deaths in the earliest
More informationMessage from. Dr Samlee Plianbangchang Regional Director, WHO South-East Asia. At the. Regional Review Meeting on Immunization
Message from Dr Samlee Plianbangchang Regional Director, WHO South-East Asia At the Regional Review Meeting on Immunization 19-23 July 2010 WHO/SEARO, New Delhi Regional Review Meeting on Immunization
More information10 th Annual African Vaccinology Course (AAVC) Cape Town 10 November 2014
Operational Challenges of Vaccination Programmes in Africa 10 th Annual African Vaccinology Course (AAVC) Cape Town 10 November 2014 Johann van den Heever: NDoH EPI Manager Outline Challenges of a Vaccination
More information50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 27 September -1 October 2010 CD50/DIV/9 ORIGINAL: SPANISH
More informationVERSION APPROVAL PROCESS NUMBER 1.0 Nina Schwalbe, Managing Director, Policy and Performance
Version No.: 1.0 Page 1 / 5 DOCUMENT ADMINISTRATION VERSION APPROVAL PROCESS DATE NUMBER 1.0 Nina Schwalbe, Managing Director, and Performance Reviewed by: GAVI Programme 23 April 2012 and Committee Approved
More informationTargeted Diseases and Immunization. Strategic plan
Targeted Diseases and Immunization Strategic plan 2008-2013 Communicable Diseases Unit WHO Regional Office for Europe Mission To provide technical support to WHO European Region Member States to ensure
More informationProgress Toward Rubella and Congenital Rubella Syndrome Elimination in the Western Hemisphere,
1 Introduction: Progress Toward Rubella and Congenital Rubella Syndrome Elimination in the Western Hemisphere, 2003-2008 1 Enhanced measles elimination activities in the Region of the Americas during the
More informationGovernment of Bangladesh
Gavi Full Country Evaluations Findings Summary of recommendations Expanded Programme on Immunization Government of Gavi Secretariat With country-level partners, target efforts on low coverage areas and
More informationGlobal Report to SAGE. Fulfillment of previous recommendations & progress highlights
Global Report to SAGE Fulfillment of previous recommendations & progress highlights SAGE Meeting, 8-10 November 2012 J.M. Okwo-Bele, WHO Outline 1 2 3 4 Global progress Regional updates- RTAGs recommendations
More informationLast mile vaccine distribution to rural health centres. Faheem Merchant
Last mile vaccine distribution to rural health centres Faheem Merchant New Global Immunization Goals 2000 - Millennium Development Goal # 4 Reduce under 5 child mortality by 2/3 between 1990 and 2015.
More informationRotavirus Vaccine. Supply and Procurement Roadmap. The Market Shaping Goal. Public Summary. Rotavirus Supply and Procurement Roadmap UPDATE 2016
The Market Shaping Goal Shape markets for vaccines and other immunisation products to achieve moderate or high levels of healthy markets dynamics. Supply and Procurement Roadmap Rotavirus Vaccine Public
More informationThe Financial Sustainability of New Vaccine Introduction in the Poorest Countries :
The Financial Sustainability of New Vaccine Introduction in the Poorest Countries : Evidence from the First Phase of GAVI (Global Alliance for Vaccines and Immunization) Patrick Lydon lydonp@who.int Session:
More informationAssessing Vaccine Safety Post Licensure. Neal A. Halsey Johns Hopkins University
Assessing Vaccine Safety Post Licensure Neal A. Halsey Johns Hopkins University Inactivated Respiratory Syncytial Virus Vaccine: 1960 s Formalin inactivated Administered to infants Minimal reactions Induced
More informationVaccine Innovation: Challenges and Opportunities to Protect Health. Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines
Vaccine Innovation: Challenges and Opportunities to Protect Health Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines Protecting Health with Vaccines HEALTH IMPROVEMENT Population Impact Guidelines
More informationGlobal Vaccine Safety Initiative Portfolio activities
Global Vaccine Safety Initiative Portfolio activities 2012-2020 Safety and Vigilance (SAV) Health Systems and Innovation (HIS) World Health Organization Geneva, Switzerland October 2013 ii Table of Contents
More informationachievements, challenges and financing
National Immunization Program: achievements, challenges and financing Lais Martins de Aquino National Immunization Program Department of Transmissible Disease Surveillance Health Surveillance Secretariat
More informationTraining for Inactivated Poliovirus Vaccine (IPV) introduction. Module 6. Inactivated poliovirus vaccine AEFI monitoring
Training for Inactivated Poliovirus Vaccine (IPV) introduction Module 6 Inactivated poliovirus vaccine AEFI monitoring Learning objectives At the end of the module, the participants will be able to: Identify
More informationTowards the Achievement of GHSA 2024 s Overarching Targets
정보화파트업무계획 [GHSA] Immunization Towards the Achievement of GHSA 2024 s Overarching Targets 2016년추진업무및 2017년업무계획 ( 사업관리 ) 7 th November 2018 Korea Centers for Disease Control and Prevention I. Overview Contents
More informationChallenges of use of cholera vaccines in Haiti and the Americas
http://www.paho.org Challenges of use of cholera vaccines in Haiti and the Americas Dr. Cuauhtémoc Ruiz Matus Comprehensive Family Immunization Program Background Topics Consultations at PAHO Challenges
More informationGAVI Alliance. Aurelia Nguyen, Director Policy & Market Shaping. IPC Meeting 30 May 2013
GAVI Alliance Aurelia Nguyen, Director Policy & Market Shaping IPC Meeting 30 May 2013 GAVI Update GAVI Alliance Overview 4 Strategic Goals 3 Market Shaping Objectives GAVI Supported Vaccines Critical
More informationVaccines. Global impact of a preventive technology. Edwin J. Asturias, MD
Vaccines Global impact of a preventive technology Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public
More informationINTERVIEW GUIDE FOR THE EPI MANAGEMENT LEVEL GENERAL INFORMATION
1 PAN AMERICAN HEALTH ORGANIZATION INTERVIEW GUIDE FOR THE EPI MANAGEMENT LEVEL GENERAL INFORMATION Date of interview: / / Interviewer s name: Management level where this interview was completed: National
More informationdeveloping countries in Latin America?
. How have rotavirus vaccines worked in developing countries in Latin America? Brendan Flannery, Pan American Health Organization, Brazil and Lúcia De Oliveira, Immunization Unit/FCH, Washington, DC 9th
More informationGAVI Role in IPV Introductions
GAVI Role in IPV Introductions Melissa Malhame 12 th WHO/UNICEF Consultation with OPV/IPV Manufacturers and National Regulatory Authorities Geneva, Switzerland, 10 GAVI vaccine support Currently supported
More information20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus since April 2009.
B. UPDATE ON THE PANDEMIC (H1N1) 2009 CD50/INF/6 (Eng.) - 7 - Annex B Background 20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus
More informationResponding to the SAGE Recommendations on Middle Income Countries Since Sarah Schmitt WHO Consultant
Responding to the SAGE Recommendations on Middle Income Countries Since 2010 Sarah Schmitt WHO Consultant 1 Plan SAGE Recommendation Expanding on the Identification of Issues WHO & Partners: Regional and
More informationIn the Name of God, the Compassionate, the Merciful. Address by DR HUSSEIN A. GEZAIRY REGIONAL DIRECTOR WHO EASTERN MEDITERRANEAN REGION.
In the Name of God, the Compassionate, the Merciful Address by DR HUSSEIN A. GEZAIRY REGIONAL DIRECTOR WHO EASTERN MEDITERRANEAN REGION on the FIRST EMIRATES INTERNATIONAL CONFERENCE ON VACCINATION Dubai,
More informationOverall presentation of IVR Strategy
Annex 3 Overall presentation of IVR Strategy Presentation to the IVR Advisory committee (IVAC) April 2007 Outline Why does WHO invest in Research & Development? What is the Initiative for Vaccine Research
More informationGAVI S VACCINE INVESTMENT STRATEGY
GAVI S VACCINE INVESTMENT STRATEGY Judith Kallenberg, Head of Policy PDVAC 22 June 2017, Geneva Reach every child www.gavi.org Gavi finances vaccines and immunisation through three routes ($9 Billion in
More informationChallenges of building a new vaccine delivery platform for LMICs
Challenges of building a new vaccine delivery platform for LMICs Terri B. Hyde, MD MPH Immunizations Systems Branch, GID, CDC 23 March 2017 Immunization in the Elderly Geneva, Switzerland What has been
More informationVaccine Safety: the risk of undermining our successes at the global level
Vaccine Safety: the risk of undermining our successes at the global level Pan-American Vaccine Safety Summit May 10, 2012 1 nsafe vaccine can have serious consequences Safety crises derail immunization
More informationAccess to vaccination in GAVI countries and at global level
Access to vaccination in GAVI countries and at global level Stefano Malvolti Director, Vaccine Implementation GAVI Alliance 15th ADVANCED COURSE OF VACCINOLOGY May 12, 2014 Global progress to MDG 4 for
More informationVaccine Safety: Its everyone s business! PHO Rounds: Nov 19, 2013
Vaccine Safety: Its everyone s business! PHO Rounds: Nov 19, 2013 Tara Harris, Nurse Consultant Shelley Deeks, Medical Director Immunization and Vaccine Preventable Diseases 1 Learning objectives 1. Describe
More informationVaccine Hesitancy: Acceptance and demand of vaccines in the Americas
Vaccine Hesitancy: Acceptance and demand of vaccines in the Americas Desiree Pastor, MD, MPH Regional Immunization Advisor Immunization Unit Department of Family, Gender and Life Course PAHO/WHO Outline
More informationReport to the. GAVI Alliance Board June 2013
Report to the GAVI Alliance Board 11-12 June 2013 Subject: Report of: Authored by: Risk Management Update Helen Evans, Deputy CEO Ciara Goldstein, Analyst, Performance Management and Adrien de Chaisemartin,
More informationPrinciples and considerations for adding a vaccine into a national immunization programme
Principles and considerations for adding a vaccine into a national immunization programme From decision to implementation Excerpted sections for the April 2012 SAGE session: Impact of vaccine introductions
More informationAdverse Events Following Immunisation
Adverse Events Following Immunisation (common, uncommon, shockin rare, and how do we know their likely cause?) Kevin Connolly Portiuncula Hospital, Sept. 18, 2017 Definitions Adverse Event (AE).. untoward
More informationHow does Gavi make vaccine investment decisions?
How does Gavi make vaccine investment decisions? Judith Kallenberg Global Vaccine and Immunization Research Forum Johannesburg, South-Africa, 16 March 2016 www.gavi.org Vaccine Investment Strategy (VIS)
More informationUpdate on Transition: the case of Honduras. Minister Dra Yolani Batres AMRO/EURO Gavi Constituency Representative Geneva June 2016
Update on Transition: the case of Honduras Minister Dra Yolani Batres AMRO/EURO Gavi Constituency Representative Geneva June 2016 GAVI Support for Honduras Content Honduras EPI Situation 2011-2016 Vaccination
More informationThe power of partnership: the GAVI Alliance Board
The power of partnership: the GAVI Alliance Board 1 GAVI s mission To save children s lives and protect people s health by increasing access to immunisation in poor countries Strategic goals 2011 2015!
More informationAppendix F. Results of the Electronic Survey of World Bank Task Team Leaders
Appendix F. Results of the Electronic Survey of World Bank Task Team Leaders 1. An electronic survey was administered in April-May 2013 to 112 World Bank Task Team Leaders of Bank-supported health projects
More informationReport to the Board 6-7 June 2018
Report to the Board 6-7 June 2018 SUBJECT: Category: PROGRAMME AND POLICY COMMITTEE CHAIR REPORT For Information Section A: Introduction This report provides the Board with an overview of the activities
More informationWHY WE RE HERE. Melinda Wharton, MD, MPH Director, Immunization Services Division. National Center for Immunization & Respiratory Diseases
National Center for Immunization & Respiratory Diseases WHY WE RE HERE Melinda Wharton, MD, MPH Director, Immunization Services Division AIM Leadership Conference February 8, 2017 Vaccines save lives.
More informationGavi initiatives for improving vaccine supply
Gavi initiatives for improving vaccine supply Melissa Malhame DCVMN, 28 October 2014 A world free from vaccine preventable diseases www.gavi.org Agenda 1. Gavi Strategy 2011-2015, and supply and procurement
More informationUNICEF Safe Injection Equipment Key highlights
Safe Injection Equipment VPPEF 03 October 2017 UNICEF Safe Injection Equipment Key highlights Nagwa Hasanin, HTC Vaccine Pharmaceutical form Route of administration Liquid Freeze- dried oral Inject Site
More informationPerspectives on Ensuring Access to Vaccines in Lower Income Countries
Perspectives on Ensuring Access to Vaccines in Lower Income Countries Greg Widmyer Deputy Director, Vaccine Delivery Foundation Merieux January 20, 2015 Bill & Melinda Gates Foundation BMGF GLOBAL PROGRAMS
More informationOverview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015
Overview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015 Ana F. Carvalho, MBA, MPH Director, Special Projects Vaccine Advocacy and Education Presented by: Jacqueline Lim
More informationManaging constrained vaccine supply: prevention and remediation Lessons learned and ways forward DVCMN Annual Meeting October Bangkok,
Managing constrained vaccine supply: prevention and remediation Lessons learned and ways forward DVCMN Annual Meeting October 5-7 2015 Bangkok, Thailand UNICEF has a key role in vaccine procurement and
More informationGavi s strategic framework 22 June 2016
Gavi s 2016 2020 strategic framework 22 June 2016 Gavi 2000-2015 Gavi 3.0 Gavi 2.0 250 million children immunised Gavi 1.0 90m children immunised 200 million children immunised 2000 2005 2006 2010 2011
More informationMonitoring results: goals, strategic objectives and indicators
page 108 Monitoring results: goals, strategic objectives and indicators 6. SURVEILLANCE Strategic Objective 4: strong immunization sytems are an integral part of a well-functioning health system. Indicator
More informationProgress Made in the Integration of EPI Costing and Planning
Volume XXXV Number 5 Immunize and Protect Your Family October 2013 Progress Made in the Integration of EPI Costing and Planning If we compare the situation of the Expanded Program on Immunization (EPI)
More informationMonitoring Vaccines Introduction. Pia Caduff-Janosa MD May 2013
Monitoring Vaccines Introduction Pia Caduff-Janosa MD May 2013 Outline Historical background Are vaccines different from other medicinal products? Different vaccines different potential safety issues Immunization
More informationUSAID Progress: The U.S. National Vaccine Plan of 1994
USAID Progress: The U.S. National Vaccine Plan of 1994 Ellyn Ogden Neal Brandes Angela Weaver Washington DC March 3, 2008 Objective 1.1/1.5 (New Vaccines) Support to GAVI for introduction of new vaccines
More informationStrengthening Health Systems and Blood Services
Strengthening Health Systems and Blood Services through a Primary Health Care Approach Dr Neelam Dhingra Coordinator Blood Transfusion safety WHO-HQ, Geneva Outline of the Presentation Blood Transfusion
More informationEdwin J. Asturias, MD Department of International Health Johns Hopkins Bloomberg School of Public Health. University del Valle in Guatemala
Vaccines: A Way to Achieve Better Health and Wealth in the Americas Edwin J. Asturias, MD Department of International Health Johns Hopkins Bloomberg School of Public Health And University del Valle in
More informationThailand Expanded Program on Immunization. Suchada Jiamsiri, MD, MPH Division of Vaccine Preventable Diseases Ministry of Public Health, Thailand
Thailand Expanded Program on Immunization Suchada Jiamsiri, MD, MPH Division of Vaccine Preventable Diseases Ministry of Public Health, Thailand Outline Expanded Program on Immunization Organization Immunization
More informationWHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES
WHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES Immunization and vaccine development in the last decade Since the Millennium Summit in 2000, immunization substantial international
More informationThank you for offering the opportunity to comment on the proposed amendments to the Pharmacy Act (Proposal #16-HLTC005).
Administration & Office of the Medical Officer of Health Telephone: 519-383-8331 160 Exmouth Street Toll-free: 1-800-667-1839 Point Edward, ON N7T 7Z6 Fax: 519-383-7092 www.lambtonhealth.on.ca Ontario
More informationRTS,S Malaria Vaccine Implementation Programme A joint initiative of GMP & IVB
RTS,S Malaria Vaccine Implementation Programme A joint initiative of GMP & IVB Update to the Malaria Policy Advisory Committee David Schellenberg, Scientific Advisor, GMP Mary Hamel, Coordinator MVIP,
More informationHistory and aims of immunisation. Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8
History and aims of immunisation Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8 Objectives To examine the history of immunisation To explain the aim of immunisation To develop
More informationPLAGUE OUTBREAK. Madagascar. External Situation Report 02. Grade
PLAGUE OUTBREAK Madagascar External Situation Report 02 Date of issue: 9 October 2017 1. Situation update Grade 2... Cases... Deaths 387 45... CFR 11.6% The outbreak of plague in Madagascar continues to
More informationVaccines Supply Shortages Challenges & Opportunities
The Pan American Health Organization (PAHO) Revolving Fund for Vaccine Procurement Vaccines Supply Shortages Challenges & Opportunities Developing Country Vaccine Manufacturers Network (DCVMN) www.paho.org/immunization
More informationWhat you need to know... Notifiable Diseases/Conditions. Alabama Department of Public Health (ADPH) Bureau of Communicable Disease - Epidemiology
What you need to know... Notifiable Diseases/Conditions Alabama Department of Public Health (ADPH) Bureau of Communicable Disease - Epidemiology 2 Objectives Understand important updates to Notifiable
More informationExpanded Programme on Immunization (EPI)
Bhutan 2017 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles containing
More informationAfghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision
Afghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data
More informationAdverse Events Following Immunisation. Kevin Connolly Limerick, Sept. 22, 2016
Adverse Events Following Immunisation Kevin Connolly Limerick, Sept. 22, 2016 Outline Abbreviations, Definitions Adverse Event (AE), Adverse Reaction (AR) or coincidence? How are AEs recorded? How are
More informationSummary of WHO Position on Rotavirus. Narendra K. Arora SAGE Member Executive Director The INCLEN Trust International New Delhi (India)
Summary of WHO Position on Rotavirus Narendra K. Arora SAGE Member Executive Director The INCLEN Trust International New Delhi (India) Presentation WHO Position Papers on Rotavirus Optimizing immunization
More informationProgramme update. Prequalification of Vaccines
Programme update Prequalification of Vaccines UN Prequalification of Medicines, Diagnostics and Vaccines 6th Consultative Stakeholder Meeting 4 April 2011 David Wood, WHO/IVB/QSS Outline Good news - A
More informationVaccine Introduction & Uptake Timing Benchmark Project
Vaccine Introduction & Uptake Timing Benchmark Project Lois Privor-Dumm Managing Director Policy, Advocacy & Communications Team Lead International Vaccine Access Center Johns Hopkins Bloomberg School
More informationSupporting State and Local Immunization Programs Brock A. Lamont, MPA Chief, Program Operations Branch Immunization Services Division
Supporting State and Local Immunization Programs Brock A. Lamont, MPA Chief, Program Operations Branch Immunization Services Division Texas Immunization Summit 2014 November 6, 2014 San Antonio, TX I do
More informationI do not have any relevant conflicts of interest to disclose.
Supporting State and Local Immunization Programs Brock A. Lamont, MPA Chief, Program Operations Branch Immunization Services Division I do not have any relevant conflicts of interest to disclose. Texas
More informationReport to the Board 6-7 June 2018
6-7 June 2018 SUBJECT: VACCINE INVESTMENT STRATEGY: SHORT LIST Agenda item: 07 Category: For Decision Section A: Introduction This report presents outcomes of the Phase II analyses for the Vaccine Investment
More informationAn aggressive approach for measles outbreak among adolescents in Barranquilla, Colombia, 2011
Closing immunity gaps in older children and adults towards measles and rubella elimination: Lessons learned and challenges. Siena, Italy, May 10-11 2016 An aggressive approach for measles outbreak among
More informationMODULE 5: Vaccine safety institutions and mechanisms. MODULE 5 Vaccine safety institutions and mechanisms
MODULE 5 Vaccine safety institutions and mechanisms Overview The general principles for the surveillance of adverse events following immunization (AEFIs) are similar in all countries. However, approaches
More informationOverview of the PAHO strategy and activities to strengthen National Regulatory Authorities in the Americas
Overview of the PAHO strategy and activities to strengthen National Regulatory Authorities in the Americas Ma. de los Angeles Cortes Regional Advisor on Vaccines and Biologicals HSS/MT Annecy, France March
More informationGavi Alliance Strategy : Goal level indicators and disease dashboard
Gavi Alliance Strategy 2016-2020: Goal level indicators and disease dashboard BOARD MEETING Peter Hansen and Hope Johnson 10-11 June 2015, Geneva Reach every child www.gavi.org Strategic enablers Goal-level
More informationHealthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.
Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy
More informationDevelopment of Vaccine Security at the Regional Level
Workshop among ASEAN countries on Opportunities for Regional Vaccine Security September 30 to October 3, 2014, Cape Panwa, Phuket, Thailand Development of Vaccine Security at the Regional Level Stephane
More informationExpanded Programme on Immunization
Expanded Programme on Immunization Expanded Programme on Immunization has been implementing the reduction of morbidity and mortality due to vaccine preventable diseases among the children aged 1 to 5 years
More informationVaccine Preventable Disease Surveillance: Overview. Thomas Cherian, WHO
Vaccine Preventable Disease Surveillance: Overview Thomas Cherian, WHO Global Framework on Immunization Monitoring and Surveillance (GFIMS) l An extension of the GIVS, published on December 07 - http://www.who.int/immunization/en/
More informationUSIIS User Documentation AFIX Assessment Reports
USIIS User Documentation AFIX Assessment Reports Overview USIIS includes new reports in the Clinic History and Batch Processes module. These reports are called AFIX reports. AFIX is an abbreviation for
More informationDr. Collins Tabu KPA Conference, 26 th April 2018 Mombasa, Kenya
Dr. Collins Tabu KPA Conference, 26 th April 2018 Mombasa, Kenya Presentation Outline Background Immunization Performance review Available Opportunities for engagement Planned and ongoing strategies- New
More information